AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

upload.jpg

AdAlta (ASX:1AD) Managing Director and CEO Dr Tim Oldham, said IPF is classed as a rare disease but one that impacts far more patients than that classification would suggest. “There are half a million patients living under this death sentence of IPF around the world today,” - The Australian reports | Read more: https://www.theaustralian.com.au/business/stockhead/news/the-asx-players-bringing-new-hope-to-ipf-sufferers/news-story/d246fb911f97dc38d8661213531e09b2

The ASX players bringing new hope to IPF sufferers